Table 1. Dynamics of the liver function tests, the conducted measures.
AST - Aspartate transaminase, ALT - Alanine transaminase, ALP - Alkaline phosphatase, LDH - Lactate dehydrogenase, GGTP - Gamma glutamyltranspeptidase
| Day | AST | ALT | Total bilirubin | Unconjugated bilirubin | Conjugated bilirubin | Total protein | ALP | Thymol test | LDH | GGTP | Measures | |||
| U/l | U/l | µmol/L | mg/dL | µmol/L | mg/dL | µmol/L | mg/dL | G/l | U/L | Units | U/L | U/L | ||
| 0 day | 581 | 1155 | 34 | 1.99 | 14.5 | 0.85 | 19.5 | 1.14 | 57.9 | 183 | 157 | Imatinib therapy was stopped | ||
| 4 day | 548.9 | 884.4 | 54.7 | 3.20 | 26.3 | 1.54 | 28.4 | 1.66 | 55.8 | 212.7 | 1.1 | 212.4 | Detoxification therapy, hepatoprotectors | |
| 16 day | 978.6 | 692.2 | 183.3 | 10.72 | 65.5 | 3.83 | 117.8 | 6.89 | 210 | 1.4 | 253.6 | Severe jaundice, adding ursodeoxycholic acid to the therapy | ||
| 20 day | 975.5 | 686.0 | 302.3 | 17.67 | 101 | 5.91 | 201.3 | 11.76 | 51.6 | 173 | 1.8 | 195.1 | Vomiting, encephalopathy | |
| 27 day | 563.1 | 538.7 | 400.2 | 23.40 | 127.9 | 7.48 | 272.3 | 15.92 | 155.9 | 1.2 | 602.4 | 126.6 | Starting administration of prednisolone 40 mg intravenously QD, continued concomitant therapy | |
| 30 day (1 month) | 258.3 | 449.1 | 303.6 | 17.75 | 86.2 | 5.04 | 217.4 | 12.71 | 52.6 | Infusion of albumin, fresh frozen plasma | ||||
| 33 day | 183.6 | 310.2 | 141.6 | 8.28 | 38.1 | 2.23 | 103.5 | 6.05 | 54.4 | 144.4 | 2.7 | 405.6 | 178.7 | |
| 36 day | 137.4 | 282.7 | 114.6 | 6.70 | 34.2 | 2.00 | 80.3 | 4.7 | 58.6 | 127.7 | 3.0 | 241.1 | ||
| 40 day | 96.9 | 209.8 | 85.8 | 5.02 | 28.2 | 1.65 | 57.6 | 3.37 | 55.2 | 105.6 | 2.00 | 353.7 | 308.4 | |
| 44 day | 55.7 | 164.4 | 76.8 | 4.49 | 29.6 | 1.73 | 47.2 | 2.76 | 57.3 | 105.9 | 1.1 | 405.2 | 109.2 | |
| 49 day | 43.8 | 126.9 | 53 | 3.10 | 19.9 | 1.16 | 33.1 | 1.94 | 58.1 | 105.6 | 2.2 | 419.8 | 85.6 | |
| 54 day | 39.4 | 111.1 | 31.7 | 1.85 | 18.7 | 1.10 | 23 | 0.75 | 62 | |||||
| 61 day (2 month) | 32.9 | 66.2 | 27.7 | 1.62 | 12.7 | 0.74 | 15.00 | 0.88 | 66.6 | Initiation of prednisolone dose reduction from 30 day of the teatment according to the scheme. The beginning of hydroxyurea taking two capsules QD according to the account appearance of leukocytosis 13.2х109/l 69 day | ||||
| 23.9 | 63.0 | 22.9 | 1.34 | 12.8 | 0.75 | 10.1 | 0.59 | 53.4 | 105.6 | 2.2 | 419.8 | 85.6 | ||
| 76 day | 26.3 | 54.2 | 26.7 | 1.56 | 17.4 | 1.02 | 9.3 | 0.54 | 66.6 | 95.8 | 1.8 | 476.9 | 58.5 | |
| 90 day (3 month) | 22.5 | 40.3 | 19.2 | 1.12 | 13.1 | 0.77 | 6.1 | 0.35 | 65.7 | 105.1 | 1.3 | 389.0 | 38.8 | A concomitant therapy was stopped, prednisolone stopped |
| 99 day | 25 | 39.3 | 30.5 | 1.78 | 22.0 | 1.29 | 8.5 | 0.49 | 58 | 107.4 | 1.1 | 361.2 | 55.7 | |
| 104 day | 20.4 | 33.2 | 13.2 | 0.77 | 10.9 | 0.64 | 2.3 | 0.13 | 67 | 109.00 | 1.4 | 367.2 | 52.4 | Initiation of second-line therapy - nilotinib 200 mg two times daily |
| 115 day | 21.2 | 27.8 | 28.1 | 1.64 | 21.6 | 1.26 | 6.5 | 0.38 | 67 | 110.5 | 403.2 | 50.1 | ||